SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT
stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the
potential benefits of stem cell transplant and high-dose monthly cyclophosphamide (Cytoxan)
in the treatment of scleroderma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)